Alnylam Pharmaceuticals Inc (ALNY) has seen a notable uptick in its stock price, reflecting positive market sentiment.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) is rising today, gaining 2.15% to close at CA$228.76. This upward movement comes amid strong investor interest in healthcare stocks, particularly those with solid financials and innovative pipelines.
Investor takeaway: Investors are increasingly optimistic about Alnylam's potential, driven by its strong earnings outlook and a solid portfolio of RNA interference therapies.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$29.42B
P/E
37.1x
52W high
$495.55
52W low
$197.81
1W change
-11.86%
Beta
0.27
Analyst Price Targets
Based on 29 analysts covering ALNY · as of Oct 5, 2026
Wall Street analysts forecast ALNY stock price to rise 65.7% over the next 12 months.
Consensus
Buy4.31 / 5.00
Avg. Target
C$371.12
+65.7% Upside
Current Price
C$223.94
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
46.2%
Annualized
90-Day Vol
71.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$187.32
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$211.00 | C$179.92 – C$247.45 |
| 60 trading days | C$198.81 | C$158.69 – C$249.06 |
| 90 trading days | C$187.32 | C$142.14 – C$246.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
2.15% Increase in Stock Price
Alnylam's stock price increase today reflects a broader trend in the healthcare sector as investors seek reliable companies with solid cash flows and growth prospects.
Bull case
Alnylam has a strong pipeline with over 25 programs targeting both rare and common conditions, setting it up for sustained growth. The company’s ability to generate significant cash flow from its existing products makes it an attractive option for investors.
Bear case
Despite the positive momentum, Alnylam's stock has dropped 44.7% year to date, raising concerns about its ability to maintain investor confidence in the face of competitive pressures and pricing challenges in the biotech sector.
Market Performance
Advertisement
Alnylam's stock performance today can be attributed to a mix of factors, including positive sentiment in the healthcare sector and the company's strong fundamentals. With a market cap of about $29.97 billion and a P/E ratio of 37.76, Alnylam remains a strong player in biotech.
Strategic Growth Initiatives
Alnylam is focused on expanding its RNA interference therapies, which are gaining traction in treating various diseases. The company has a robust pipeline with multiple pivotal studies underway, positioning it for potential future revenue growth.
Investor Sentiment
The recent rise in Alnylam's stock price reflects growing confidence among investors in the company's ability to navigate market challenges and capitalize on its innovative drug development strategy. As healthcare evolves, Alnylam's focus on rare diseases and cutting-edge therapies may provide significant long-term value.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
